



ADULT MEDICATION GUIDELINE

Carboprost (Prostaglandin F2 Alpha)

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Restricted](#)

[SAS Category A](#) (item requires approval by TGA)

[HIGH RISK Medication](#) 

Contraindicated in active cardiac, pulmonary (including significant history of asthma), renal, or hepatic disease.

Medication Class

Prostaglandin, oxytocic

Presentation

Vial: 250micrograms/mL

Storage

Store at 2 to 8 °C. Do not freeze.

Dose

Postpartum Haemorrhage (unresponsive to conventional therapy)

Intramuscular: 250micrograms, in repeated doses as required at intervals of not less than 15

minutes to a maximum total cumulative dose of 2mg (i.e. up to 8 doses).

First dose may be given outside of the operating theatre; The requirement for additional doses is an indication for a Category 1 transfer to the operating theatre.

Administration

IM injection only

Refer to the [Australian Injectable Drugs Handbook](#)

Carboprost must NOT be given intravenously

Monitoring

Monitor for severe hypertension and bronchospasm. Diarrhoea, nausea, vomiting, flushing and a transient increase in body temperature after the injection are common.

Pregnancy

1st Trimester: Contraindicated

2nd Trimester: Contraindicated

3rd Trimester: Contraindicated

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Commonly used in obstetrics without complications in breastfeeding

Mothers. For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Comments

[Carboprost Consumer Medicines Information Leaflet](#)

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

[Postpartum complications](#)

[Caesarean birth](#)









WNHS Pharmaceutical and Medicines Management Guidelines:

[Storage of Fridge Medications and Vaccines](#)

[Return & Disposal of Medications](#)

References

- Society of Hospital Pharmacists of Australia. Carboprost. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2022 May 26]. Available from: <http://aidh.hcn.com.au>
- Truven Health Analytics. Carboprost. In: Micromedex [Internet]. Greenwood Village (CO): Truven Health Analytics; 2022 [cited 2022 May 26]. Available from: <http://www.micromedexsolutions.com/>
- RANZCOG. Management of Postpartum haemorrhage (C-Obs-43). [Internet]. 2021 [cited 2022 May 26]. Available from: [https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Management-of-Postpartum-haemorrhage_\(C-Obs-43\).pdf?ext=.pdf](https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Management-of-Postpartum-haemorrhage_(C-Obs-43).pdf?ext=.pdf)
- Mavrides E, Allard S, Chandraharan E, Collins P, Green L, Hunt BJ, Riris S, Thomson AJ on behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage. BJOG 2016;124:e106–e149. [cited 2022 May 26] Available from: https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/RCOG-Prevention-and-Management-of-Postpartum-Haemorrhage-2016.pdf?ext=.pdf
- Hale TW. Carboprost. In: Hale's Meds [Internet]. New York: Springer Publishing Company; 2016 [cited 2022 May 26]. Available from: <https://www-halesmeds-com>
- Briggs GC, Freeman RK. Carboprost. In: Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk [Internet]. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2015 [cited 2022 May 26]. Available from: Books@OVID
- Sir Charles Gairdner Osborne Park Health Care Group. Guidelines for the use of carboprost at OPH. 2022 [cited 2022 Jul 21].

Keywords	Carboprost, prostaglandin, prostaglandin F2 alpha, F2 alpha, postpartum haemorrhage				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	06/2015	Last Reviewed:	11/10/2022	Review Date:	11/10/2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/11/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input checked="" type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.